TECHNOLOGY IN CANCER RESEARCH & TREATMENT-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=953030, encodeId=72a3953030a8, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：腮腺癌 经验分享：2021年1月4日投稿，2021年03月17日返回评审建议，两个评审均为小修，3.19反修，3月29日接收，从投稿到接收不到3个月。之前投过一次被拒稿，一共投两次，拒稿率50%。用了SEER数据库建预后模型与TNM分期比较。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/c69458c5aae644fca7458ac4ee7d3dc5/97598ec05e2943409cd351605fd99203.jpg, createdBy=75b92509278, createdName=Lei-Lei, createdTime=Thu Apr 01 10:57:29 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999431, encodeId=c35699943123, content=小修修回去都10天了，还没有消息，各位大神知道这个杂志小修修回一般几天给消息啊等的好焦急啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f634299025, createdName=wangle1256bai, createdTime=Wed Jul 14 16:08:29 CST 2021, time=2021-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077882, encodeId=75f210e78824d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤学;Medicine;肿瘤 经验分享：审稿了这个杂志几篇文章，最后拒了两篇，接收了两篇，总体来说杂志对数据量和创新性要求不高，有一些seer数据库的文章和纯临床文章也会接收，审稿周期可能看寻找审稿人过程顺不顺利，长短不一, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLsIgn717B1AlcC2NErrfSbC5l68ia3bYc7zzhOAFibyeFcu4x6JQcCcqJmy08br2e0M72TM5To33pw/132, createdBy=a7af2090460, createdName=dragon0211, createdTime=Tue Dec 07 22:13:46 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118737, encodeId=50ff2118e377e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：做个记录，一篇关于罕见转移的临床回顾性研究…… 20230306 submitted 0308 Administrative checks complete……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=997xiu, createdTime=Fri Mar 10 23:08:33 CST 2023, time=2023-03-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1230573, encodeId=670a12305e38a, content=偏重的研究方向：乳腺癌 经验分享：记录一下 6月29日开始邀请审稿人 7月4日仍然还在邀请中........ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=摩西摩西, createdTime=Mon Jul 04 22:29:43 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959975, encodeId=86809599e5dd, content=有没有人遇到过这种情况，一审两个审稿人意见很中肯，修回三天了，状态又成了Selecting Referees，这是什么意思，是在找之前的审稿人还是又重新送审了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1aae2944946, createdName=1033927265, createdTime=Sat Apr 24 10:00:03 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904502, encodeId=6a75904502f4, content=投稿一个月了，现在还是Securing Referees，请问是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKJn00QRPUIQRIfRn1gJOYBXibwFW4ibQuO09ObUInlL9wHCMQW2ADGW7Oibhr7Hqw6TN04s4wQ2z4Qg/132, createdBy=2b8d2258604, createdName=aciding, createdTime=Thu Dec 03 08:41:57 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074335, encodeId=3bbb10e433543, content=5月投稿，这个月初于被接收了，这个期刊审稿速度我觉得还可以啊！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=ASD8888, createdTime=Fri Nov 26 21:50:40 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222662, encodeId=e6c412226621d, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：第一篇SCI 一个月左右返回意见：大修，返修后20天接收还是挺快的不知道什么时候出PROOF, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a0e5183979, createdName=14701b4bm56暂无昵称, createdTime=Thu May 26 21:12:12 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2107072, encodeId=9185210e072ab, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：消化道肿瘤;水凝胶 经验分享：我会经常在梅斯上看大家的经验，想着我要是有经验了也来给大家反馈一下，互相帮助共渡毕业大关： 2022-6-21号投稿 Initial Checks， 6-23号更新投稿 Initial Checks， 6-24号Initial checks have been completed and Editor assignment is being determined， 6-27号Editor assessment The Editor is assessing your submission for peer review， 6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received， 7-4号邮件告知UnderReview，Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews， 8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received， 8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission， 8-19号通知大修， 9-11号R1修回， 10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission， 11-06号催稿信， 12-01号通知二次返修， 12-13号R2修回， 12-22号Accept Admin completing pre-production checks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211124/1e5cd5d4efd7465caf5bd5b725ef80a1/3ece342b14e94d08bab19d7ff6d8dadd.jpg, createdBy=a3015646862, createdName=不懂科研的科研狗子, createdTime=Thu Dec 22 16:38:20 CST 2022, time=2022-12-22, status=1, ipAttribution=北京)]

2021-04-01 Lei-Lei

审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向：腮腺癌
经验分享：2021年1月4日投稿，2021年03月17日返回评审建议，两个评审均为小修，3.19反修，3月29日接收，从投稿到接收不到3个月。之前投过一次被拒稿，一共投两次，拒稿率50%。用了SEER数据库建预后模型与TNM分期比较。

58 16

展开16条回复

[GetPortalCommentsPageByObjectIdResponse(id=953030, encodeId=72a3953030a8, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：腮腺癌 经验分享：2021年1月4日投稿，2021年03月17日返回评审建议，两个评审均为小修，3.19反修，3月29日接收，从投稿到接收不到3个月。之前投过一次被拒稿，一共投两次，拒稿率50%。用了SEER数据库建预后模型与TNM分期比较。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/c69458c5aae644fca7458ac4ee7d3dc5/97598ec05e2943409cd351605fd99203.jpg, createdBy=75b92509278, createdName=Lei-Lei, createdTime=Thu Apr 01 10:57:29 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999431, encodeId=c35699943123, content=小修修回去都10天了，还没有消息，各位大神知道这个杂志小修修回一般几天给消息啊等的好焦急啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f634299025, createdName=wangle1256bai, createdTime=Wed Jul 14 16:08:29 CST 2021, time=2021-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077882, encodeId=75f210e78824d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤学;Medicine;肿瘤 经验分享：审稿了这个杂志几篇文章，最后拒了两篇，接收了两篇，总体来说杂志对数据量和创新性要求不高，有一些seer数据库的文章和纯临床文章也会接收，审稿周期可能看寻找审稿人过程顺不顺利，长短不一, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLsIgn717B1AlcC2NErrfSbC5l68ia3bYc7zzhOAFibyeFcu4x6JQcCcqJmy08br2e0M72TM5To33pw/132, createdBy=a7af2090460, createdName=dragon0211, createdTime=Tue Dec 07 22:13:46 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118737, encodeId=50ff2118e377e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：做个记录，一篇关于罕见转移的临床回顾性研究…… 20230306 submitted 0308 Administrative checks complete……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=997xiu, createdTime=Fri Mar 10 23:08:33 CST 2023, time=2023-03-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1230573, encodeId=670a12305e38a, content=偏重的研究方向：乳腺癌 经验分享：记录一下 6月29日开始邀请审稿人 7月4日仍然还在邀请中........ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=摩西摩西, createdTime=Mon Jul 04 22:29:43 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959975, encodeId=86809599e5dd, content=有没有人遇到过这种情况，一审两个审稿人意见很中肯，修回三天了，状态又成了Selecting Referees，这是什么意思，是在找之前的审稿人还是又重新送审了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1aae2944946, createdName=1033927265, createdTime=Sat Apr 24 10:00:03 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904502, encodeId=6a75904502f4, content=投稿一个月了，现在还是Securing Referees，请问是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKJn00QRPUIQRIfRn1gJOYBXibwFW4ibQuO09ObUInlL9wHCMQW2ADGW7Oibhr7Hqw6TN04s4wQ2z4Qg/132, createdBy=2b8d2258604, createdName=aciding, createdTime=Thu Dec 03 08:41:57 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074335, encodeId=3bbb10e433543, content=5月投稿，这个月初于被接收了，这个期刊审稿速度我觉得还可以啊！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=ASD8888, createdTime=Fri Nov 26 21:50:40 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222662, encodeId=e6c412226621d, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：第一篇SCI 一个月左右返回意见：大修，返修后20天接收还是挺快的不知道什么时候出PROOF, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a0e5183979, createdName=14701b4bm56暂无昵称, createdTime=Thu May 26 21:12:12 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2107072, encodeId=9185210e072ab, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：消化道肿瘤;水凝胶 经验分享：我会经常在梅斯上看大家的经验，想着我要是有经验了也来给大家反馈一下，互相帮助共渡毕业大关： 2022-6-21号投稿 Initial Checks， 6-23号更新投稿 Initial Checks， 6-24号Initial checks have been completed and Editor assignment is being determined， 6-27号Editor assessment The Editor is assessing your submission for peer review， 6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received， 7-4号邮件告知UnderReview，Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews， 8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received， 8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission， 8-19号通知大修， 9-11号R1修回， 10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission， 11-06号催稿信， 12-01号通知二次返修， 12-13号R2修回， 12-22号Accept Admin completing pre-production checks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211124/1e5cd5d4efd7465caf5bd5b725ef80a1/3ece342b14e94d08bab19d7ff6d8dadd.jpg, createdBy=a3015646862, createdName=不懂科研的科研狗子, createdTime=Thu Dec 22 16:38:20 CST 2022, time=2022-12-22, status=1, ipAttribution=北京)]

2021-07-14 wangle1256bai

小修修回去都10天了，还没有消息，各位大神知道这个杂志小修修回一般几天给消息啊等的好焦急啊

93 15

展开15条回复

[GetPortalCommentsPageByObjectIdResponse(id=953030, encodeId=72a3953030a8, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：腮腺癌 经验分享：2021年1月4日投稿，2021年03月17日返回评审建议，两个评审均为小修，3.19反修，3月29日接收，从投稿到接收不到3个月。之前投过一次被拒稿，一共投两次，拒稿率50%。用了SEER数据库建预后模型与TNM分期比较。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/c69458c5aae644fca7458ac4ee7d3dc5/97598ec05e2943409cd351605fd99203.jpg, createdBy=75b92509278, createdName=Lei-Lei, createdTime=Thu Apr 01 10:57:29 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999431, encodeId=c35699943123, content=小修修回去都10天了，还没有消息，各位大神知道这个杂志小修修回一般几天给消息啊等的好焦急啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f634299025, createdName=wangle1256bai, createdTime=Wed Jul 14 16:08:29 CST 2021, time=2021-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077882, encodeId=75f210e78824d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤学;Medicine;肿瘤 经验分享：审稿了这个杂志几篇文章，最后拒了两篇，接收了两篇，总体来说杂志对数据量和创新性要求不高，有一些seer数据库的文章和纯临床文章也会接收，审稿周期可能看寻找审稿人过程顺不顺利，长短不一, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLsIgn717B1AlcC2NErrfSbC5l68ia3bYc7zzhOAFibyeFcu4x6JQcCcqJmy08br2e0M72TM5To33pw/132, createdBy=a7af2090460, createdName=dragon0211, createdTime=Tue Dec 07 22:13:46 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118737, encodeId=50ff2118e377e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：做个记录，一篇关于罕见转移的临床回顾性研究…… 20230306 submitted 0308 Administrative checks complete……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=997xiu, createdTime=Fri Mar 10 23:08:33 CST 2023, time=2023-03-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1230573, encodeId=670a12305e38a, content=偏重的研究方向：乳腺癌 经验分享：记录一下 6月29日开始邀请审稿人 7月4日仍然还在邀请中........ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=摩西摩西, createdTime=Mon Jul 04 22:29:43 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959975, encodeId=86809599e5dd, content=有没有人遇到过这种情况，一审两个审稿人意见很中肯，修回三天了，状态又成了Selecting Referees，这是什么意思，是在找之前的审稿人还是又重新送审了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1aae2944946, createdName=1033927265, createdTime=Sat Apr 24 10:00:03 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904502, encodeId=6a75904502f4, content=投稿一个月了，现在还是Securing Referees，请问是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKJn00QRPUIQRIfRn1gJOYBXibwFW4ibQuO09ObUInlL9wHCMQW2ADGW7Oibhr7Hqw6TN04s4wQ2z4Qg/132, createdBy=2b8d2258604, createdName=aciding, createdTime=Thu Dec 03 08:41:57 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074335, encodeId=3bbb10e433543, content=5月投稿，这个月初于被接收了，这个期刊审稿速度我觉得还可以啊！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=ASD8888, createdTime=Fri Nov 26 21:50:40 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222662, encodeId=e6c412226621d, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：第一篇SCI 一个月左右返回意见：大修，返修后20天接收还是挺快的不知道什么时候出PROOF, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a0e5183979, createdName=14701b4bm56暂无昵称, createdTime=Thu May 26 21:12:12 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2107072, encodeId=9185210e072ab, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：消化道肿瘤;水凝胶 经验分享：我会经常在梅斯上看大家的经验，想着我要是有经验了也来给大家反馈一下，互相帮助共渡毕业大关： 2022-6-21号投稿 Initial Checks， 6-23号更新投稿 Initial Checks， 6-24号Initial checks have been completed and Editor assignment is being determined， 6-27号Editor assessment The Editor is assessing your submission for peer review， 6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received， 7-4号邮件告知UnderReview，Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews， 8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received， 8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission， 8-19号通知大修， 9-11号R1修回， 10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission， 11-06号催稿信， 12-01号通知二次返修， 12-13号R2修回， 12-22号Accept Admin completing pre-production checks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211124/1e5cd5d4efd7465caf5bd5b725ef80a1/3ece342b14e94d08bab19d7ff6d8dadd.jpg, createdBy=a3015646862, createdName=不懂科研的科研狗子, createdTime=Thu Dec 22 16:38:20 CST 2022, time=2022-12-22, status=1, ipAttribution=北京)]

2021-12-07 dragon0211

审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤学;Medicine;肿瘤
经验分享：审稿了这个杂志几篇文章，最后拒了两篇，接收了两篇，总体来说杂志对数据量和创新性要求不高，有一些seer数据库的文章和纯临床文章也会接收，审稿周期可能看寻找审稿人过程顺不顺利，长短不一

66 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=953030, encodeId=72a3953030a8, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：腮腺癌 经验分享：2021年1月4日投稿，2021年03月17日返回评审建议，两个评审均为小修，3.19反修，3月29日接收，从投稿到接收不到3个月。之前投过一次被拒稿，一共投两次，拒稿率50%。用了SEER数据库建预后模型与TNM分期比较。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/c69458c5aae644fca7458ac4ee7d3dc5/97598ec05e2943409cd351605fd99203.jpg, createdBy=75b92509278, createdName=Lei-Lei, createdTime=Thu Apr 01 10:57:29 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999431, encodeId=c35699943123, content=小修修回去都10天了，还没有消息，各位大神知道这个杂志小修修回一般几天给消息啊等的好焦急啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f634299025, createdName=wangle1256bai, createdTime=Wed Jul 14 16:08:29 CST 2021, time=2021-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077882, encodeId=75f210e78824d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤学;Medicine;肿瘤 经验分享：审稿了这个杂志几篇文章，最后拒了两篇，接收了两篇，总体来说杂志对数据量和创新性要求不高，有一些seer数据库的文章和纯临床文章也会接收，审稿周期可能看寻找审稿人过程顺不顺利，长短不一, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLsIgn717B1AlcC2NErrfSbC5l68ia3bYc7zzhOAFibyeFcu4x6JQcCcqJmy08br2e0M72TM5To33pw/132, createdBy=a7af2090460, createdName=dragon0211, createdTime=Tue Dec 07 22:13:46 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118737, encodeId=50ff2118e377e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：做个记录，一篇关于罕见转移的临床回顾性研究…… 20230306 submitted 0308 Administrative checks complete……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=997xiu, createdTime=Fri Mar 10 23:08:33 CST 2023, time=2023-03-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1230573, encodeId=670a12305e38a, content=偏重的研究方向：乳腺癌 经验分享：记录一下 6月29日开始邀请审稿人 7月4日仍然还在邀请中........ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=摩西摩西, createdTime=Mon Jul 04 22:29:43 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959975, encodeId=86809599e5dd, content=有没有人遇到过这种情况，一审两个审稿人意见很中肯，修回三天了，状态又成了Selecting Referees，这是什么意思，是在找之前的审稿人还是又重新送审了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1aae2944946, createdName=1033927265, createdTime=Sat Apr 24 10:00:03 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904502, encodeId=6a75904502f4, content=投稿一个月了，现在还是Securing Referees，请问是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKJn00QRPUIQRIfRn1gJOYBXibwFW4ibQuO09ObUInlL9wHCMQW2ADGW7Oibhr7Hqw6TN04s4wQ2z4Qg/132, createdBy=2b8d2258604, createdName=aciding, createdTime=Thu Dec 03 08:41:57 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074335, encodeId=3bbb10e433543, content=5月投稿，这个月初于被接收了，这个期刊审稿速度我觉得还可以啊！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=ASD8888, createdTime=Fri Nov 26 21:50:40 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222662, encodeId=e6c412226621d, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：第一篇SCI 一个月左右返回意见：大修，返修后20天接收还是挺快的不知道什么时候出PROOF, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a0e5183979, createdName=14701b4bm56暂无昵称, createdTime=Thu May 26 21:12:12 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2107072, encodeId=9185210e072ab, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：消化道肿瘤;水凝胶 经验分享：我会经常在梅斯上看大家的经验，想着我要是有经验了也来给大家反馈一下，互相帮助共渡毕业大关： 2022-6-21号投稿 Initial Checks， 6-23号更新投稿 Initial Checks， 6-24号Initial checks have been completed and Editor assignment is being determined， 6-27号Editor assessment The Editor is assessing your submission for peer review， 6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received， 7-4号邮件告知UnderReview，Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews， 8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received， 8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission， 8-19号通知大修， 9-11号R1修回， 10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission， 11-06号催稿信， 12-01号通知二次返修， 12-13号R2修回， 12-22号Accept Admin completing pre-production checks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211124/1e5cd5d4efd7465caf5bd5b725ef80a1/3ece342b14e94d08bab19d7ff6d8dadd.jpg, createdBy=a3015646862, createdName=不懂科研的科研狗子, createdTime=Thu Dec 22 16:38:20 CST 2022, time=2022-12-22, status=1, ipAttribution=北京)]

2023-03-10 997xiu 来自上海

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：做个记录，一篇关于罕见转移的临床回顾性研究……
20230306 submitted
0308 Administrative checks complete……

52 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=953030, encodeId=72a3953030a8, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：腮腺癌 经验分享：2021年1月4日投稿，2021年03月17日返回评审建议，两个评审均为小修，3.19反修，3月29日接收，从投稿到接收不到3个月。之前投过一次被拒稿，一共投两次，拒稿率50%。用了SEER数据库建预后模型与TNM分期比较。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/c69458c5aae644fca7458ac4ee7d3dc5/97598ec05e2943409cd351605fd99203.jpg, createdBy=75b92509278, createdName=Lei-Lei, createdTime=Thu Apr 01 10:57:29 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999431, encodeId=c35699943123, content=小修修回去都10天了，还没有消息，各位大神知道这个杂志小修修回一般几天给消息啊等的好焦急啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f634299025, createdName=wangle1256bai, createdTime=Wed Jul 14 16:08:29 CST 2021, time=2021-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077882, encodeId=75f210e78824d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤学;Medicine;肿瘤 经验分享：审稿了这个杂志几篇文章，最后拒了两篇，接收了两篇，总体来说杂志对数据量和创新性要求不高，有一些seer数据库的文章和纯临床文章也会接收，审稿周期可能看寻找审稿人过程顺不顺利，长短不一, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLsIgn717B1AlcC2NErrfSbC5l68ia3bYc7zzhOAFibyeFcu4x6JQcCcqJmy08br2e0M72TM5To33pw/132, createdBy=a7af2090460, createdName=dragon0211, createdTime=Tue Dec 07 22:13:46 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118737, encodeId=50ff2118e377e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：做个记录，一篇关于罕见转移的临床回顾性研究…… 20230306 submitted 0308 Administrative checks complete……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=997xiu, createdTime=Fri Mar 10 23:08:33 CST 2023, time=2023-03-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1230573, encodeId=670a12305e38a, content=偏重的研究方向：乳腺癌 经验分享：记录一下 6月29日开始邀请审稿人 7月4日仍然还在邀请中........ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=摩西摩西, createdTime=Mon Jul 04 22:29:43 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959975, encodeId=86809599e5dd, content=有没有人遇到过这种情况，一审两个审稿人意见很中肯，修回三天了，状态又成了Selecting Referees，这是什么意思，是在找之前的审稿人还是又重新送审了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1aae2944946, createdName=1033927265, createdTime=Sat Apr 24 10:00:03 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904502, encodeId=6a75904502f4, content=投稿一个月了，现在还是Securing Referees，请问是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKJn00QRPUIQRIfRn1gJOYBXibwFW4ibQuO09ObUInlL9wHCMQW2ADGW7Oibhr7Hqw6TN04s4wQ2z4Qg/132, createdBy=2b8d2258604, createdName=aciding, createdTime=Thu Dec 03 08:41:57 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074335, encodeId=3bbb10e433543, content=5月投稿，这个月初于被接收了，这个期刊审稿速度我觉得还可以啊！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=ASD8888, createdTime=Fri Nov 26 21:50:40 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222662, encodeId=e6c412226621d, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：第一篇SCI 一个月左右返回意见：大修，返修后20天接收还是挺快的不知道什么时候出PROOF, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a0e5183979, createdName=14701b4bm56暂无昵称, createdTime=Thu May 26 21:12:12 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2107072, encodeId=9185210e072ab, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：消化道肿瘤;水凝胶 经验分享：我会经常在梅斯上看大家的经验，想着我要是有经验了也来给大家反馈一下，互相帮助共渡毕业大关： 2022-6-21号投稿 Initial Checks， 6-23号更新投稿 Initial Checks， 6-24号Initial checks have been completed and Editor assignment is being determined， 6-27号Editor assessment The Editor is assessing your submission for peer review， 6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received， 7-4号邮件告知UnderReview，Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews， 8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received， 8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission， 8-19号通知大修， 9-11号R1修回， 10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission， 11-06号催稿信， 12-01号通知二次返修， 12-13号R2修回， 12-22号Accept Admin completing pre-production checks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211124/1e5cd5d4efd7465caf5bd5b725ef80a1/3ece342b14e94d08bab19d7ff6d8dadd.jpg, createdBy=a3015646862, createdName=不懂科研的科研狗子, createdTime=Thu Dec 22 16:38:20 CST 2022, time=2022-12-22, status=1, ipAttribution=北京)]

2022-07-04 摩西摩西

偏重的研究方向：乳腺癌
经验分享：记录一下
6月29日开始邀请审稿人
7月4日仍然还在邀请中........

46 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=953030, encodeId=72a3953030a8, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：腮腺癌 经验分享：2021年1月4日投稿，2021年03月17日返回评审建议，两个评审均为小修，3.19反修，3月29日接收，从投稿到接收不到3个月。之前投过一次被拒稿，一共投两次，拒稿率50%。用了SEER数据库建预后模型与TNM分期比较。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/c69458c5aae644fca7458ac4ee7d3dc5/97598ec05e2943409cd351605fd99203.jpg, createdBy=75b92509278, createdName=Lei-Lei, createdTime=Thu Apr 01 10:57:29 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999431, encodeId=c35699943123, content=小修修回去都10天了，还没有消息，各位大神知道这个杂志小修修回一般几天给消息啊等的好焦急啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f634299025, createdName=wangle1256bai, createdTime=Wed Jul 14 16:08:29 CST 2021, time=2021-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077882, encodeId=75f210e78824d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤学;Medicine;肿瘤 经验分享：审稿了这个杂志几篇文章，最后拒了两篇，接收了两篇，总体来说杂志对数据量和创新性要求不高，有一些seer数据库的文章和纯临床文章也会接收，审稿周期可能看寻找审稿人过程顺不顺利，长短不一, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLsIgn717B1AlcC2NErrfSbC5l68ia3bYc7zzhOAFibyeFcu4x6JQcCcqJmy08br2e0M72TM5To33pw/132, createdBy=a7af2090460, createdName=dragon0211, createdTime=Tue Dec 07 22:13:46 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118737, encodeId=50ff2118e377e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：做个记录，一篇关于罕见转移的临床回顾性研究…… 20230306 submitted 0308 Administrative checks complete……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=997xiu, createdTime=Fri Mar 10 23:08:33 CST 2023, time=2023-03-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1230573, encodeId=670a12305e38a, content=偏重的研究方向：乳腺癌 经验分享：记录一下 6月29日开始邀请审稿人 7月4日仍然还在邀请中........ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=摩西摩西, createdTime=Mon Jul 04 22:29:43 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959975, encodeId=86809599e5dd, content=有没有人遇到过这种情况，一审两个审稿人意见很中肯，修回三天了，状态又成了Selecting Referees，这是什么意思，是在找之前的审稿人还是又重新送审了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1aae2944946, createdName=1033927265, createdTime=Sat Apr 24 10:00:03 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904502, encodeId=6a75904502f4, content=投稿一个月了，现在还是Securing Referees，请问是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKJn00QRPUIQRIfRn1gJOYBXibwFW4ibQuO09ObUInlL9wHCMQW2ADGW7Oibhr7Hqw6TN04s4wQ2z4Qg/132, createdBy=2b8d2258604, createdName=aciding, createdTime=Thu Dec 03 08:41:57 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074335, encodeId=3bbb10e433543, content=5月投稿，这个月初于被接收了，这个期刊审稿速度我觉得还可以啊！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=ASD8888, createdTime=Fri Nov 26 21:50:40 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222662, encodeId=e6c412226621d, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：第一篇SCI 一个月左右返回意见：大修，返修后20天接收还是挺快的不知道什么时候出PROOF, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a0e5183979, createdName=14701b4bm56暂无昵称, createdTime=Thu May 26 21:12:12 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2107072, encodeId=9185210e072ab, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：消化道肿瘤;水凝胶 经验分享：我会经常在梅斯上看大家的经验，想着我要是有经验了也来给大家反馈一下，互相帮助共渡毕业大关： 2022-6-21号投稿 Initial Checks， 6-23号更新投稿 Initial Checks， 6-24号Initial checks have been completed and Editor assignment is being determined， 6-27号Editor assessment The Editor is assessing your submission for peer review， 6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received， 7-4号邮件告知UnderReview，Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews， 8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received， 8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission， 8-19号通知大修， 9-11号R1修回， 10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission， 11-06号催稿信， 12-01号通知二次返修， 12-13号R2修回， 12-22号Accept Admin completing pre-production checks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211124/1e5cd5d4efd7465caf5bd5b725ef80a1/3ece342b14e94d08bab19d7ff6d8dadd.jpg, createdBy=a3015646862, createdName=不懂科研的科研狗子, createdTime=Thu Dec 22 16:38:20 CST 2022, time=2022-12-22, status=1, ipAttribution=北京)]

2021-04-24 1033927265

有没有人遇到过这种情况，一审两个审稿人意见很中肯，修回三天了，状态又成了Selecting Referees，这是什么意思，是在找之前的审稿人还是又重新送审了

81 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=953030, encodeId=72a3953030a8, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：腮腺癌 经验分享：2021年1月4日投稿，2021年03月17日返回评审建议，两个评审均为小修，3.19反修，3月29日接收，从投稿到接收不到3个月。之前投过一次被拒稿，一共投两次，拒稿率50%。用了SEER数据库建预后模型与TNM分期比较。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/c69458c5aae644fca7458ac4ee7d3dc5/97598ec05e2943409cd351605fd99203.jpg, createdBy=75b92509278, createdName=Lei-Lei, createdTime=Thu Apr 01 10:57:29 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999431, encodeId=c35699943123, content=小修修回去都10天了，还没有消息，各位大神知道这个杂志小修修回一般几天给消息啊等的好焦急啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f634299025, createdName=wangle1256bai, createdTime=Wed Jul 14 16:08:29 CST 2021, time=2021-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077882, encodeId=75f210e78824d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤学;Medicine;肿瘤 经验分享：审稿了这个杂志几篇文章，最后拒了两篇，接收了两篇，总体来说杂志对数据量和创新性要求不高，有一些seer数据库的文章和纯临床文章也会接收，审稿周期可能看寻找审稿人过程顺不顺利，长短不一, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLsIgn717B1AlcC2NErrfSbC5l68ia3bYc7zzhOAFibyeFcu4x6JQcCcqJmy08br2e0M72TM5To33pw/132, createdBy=a7af2090460, createdName=dragon0211, createdTime=Tue Dec 07 22:13:46 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118737, encodeId=50ff2118e377e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：做个记录，一篇关于罕见转移的临床回顾性研究…… 20230306 submitted 0308 Administrative checks complete……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=997xiu, createdTime=Fri Mar 10 23:08:33 CST 2023, time=2023-03-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1230573, encodeId=670a12305e38a, content=偏重的研究方向：乳腺癌 经验分享：记录一下 6月29日开始邀请审稿人 7月4日仍然还在邀请中........ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=摩西摩西, createdTime=Mon Jul 04 22:29:43 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959975, encodeId=86809599e5dd, content=有没有人遇到过这种情况，一审两个审稿人意见很中肯，修回三天了，状态又成了Selecting Referees，这是什么意思，是在找之前的审稿人还是又重新送审了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1aae2944946, createdName=1033927265, createdTime=Sat Apr 24 10:00:03 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904502, encodeId=6a75904502f4, content=投稿一个月了，现在还是Securing Referees，请问是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKJn00QRPUIQRIfRn1gJOYBXibwFW4ibQuO09ObUInlL9wHCMQW2ADGW7Oibhr7Hqw6TN04s4wQ2z4Qg/132, createdBy=2b8d2258604, createdName=aciding, createdTime=Thu Dec 03 08:41:57 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074335, encodeId=3bbb10e433543, content=5月投稿，这个月初于被接收了，这个期刊审稿速度我觉得还可以啊！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=ASD8888, createdTime=Fri Nov 26 21:50:40 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222662, encodeId=e6c412226621d, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：第一篇SCI 一个月左右返回意见：大修，返修后20天接收还是挺快的不知道什么时候出PROOF, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a0e5183979, createdName=14701b4bm56暂无昵称, createdTime=Thu May 26 21:12:12 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2107072, encodeId=9185210e072ab, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：消化道肿瘤;水凝胶 经验分享：我会经常在梅斯上看大家的经验，想着我要是有经验了也来给大家反馈一下，互相帮助共渡毕业大关： 2022-6-21号投稿 Initial Checks， 6-23号更新投稿 Initial Checks， 6-24号Initial checks have been completed and Editor assignment is being determined， 6-27号Editor assessment The Editor is assessing your submission for peer review， 6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received， 7-4号邮件告知UnderReview，Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews， 8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received， 8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission， 8-19号通知大修， 9-11号R1修回， 10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission， 11-06号催稿信， 12-01号通知二次返修， 12-13号R2修回， 12-22号Accept Admin completing pre-production checks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211124/1e5cd5d4efd7465caf5bd5b725ef80a1/3ece342b14e94d08bab19d7ff6d8dadd.jpg, createdBy=a3015646862, createdName=不懂科研的科研狗子, createdTime=Thu Dec 22 16:38:20 CST 2022, time=2022-12-22, status=1, ipAttribution=北京)]

2020-12-03 aciding

投稿一个月了，现在还是Securing Referees，请问是什么情况

184 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=953030, encodeId=72a3953030a8, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：腮腺癌 经验分享：2021年1月4日投稿，2021年03月17日返回评审建议，两个评审均为小修，3.19反修，3月29日接收，从投稿到接收不到3个月。之前投过一次被拒稿，一共投两次，拒稿率50%。用了SEER数据库建预后模型与TNM分期比较。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/c69458c5aae644fca7458ac4ee7d3dc5/97598ec05e2943409cd351605fd99203.jpg, createdBy=75b92509278, createdName=Lei-Lei, createdTime=Thu Apr 01 10:57:29 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999431, encodeId=c35699943123, content=小修修回去都10天了，还没有消息，各位大神知道这个杂志小修修回一般几天给消息啊等的好焦急啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f634299025, createdName=wangle1256bai, createdTime=Wed Jul 14 16:08:29 CST 2021, time=2021-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077882, encodeId=75f210e78824d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤学;Medicine;肿瘤 经验分享：审稿了这个杂志几篇文章，最后拒了两篇，接收了两篇，总体来说杂志对数据量和创新性要求不高，有一些seer数据库的文章和纯临床文章也会接收，审稿周期可能看寻找审稿人过程顺不顺利，长短不一, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLsIgn717B1AlcC2NErrfSbC5l68ia3bYc7zzhOAFibyeFcu4x6JQcCcqJmy08br2e0M72TM5To33pw/132, createdBy=a7af2090460, createdName=dragon0211, createdTime=Tue Dec 07 22:13:46 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118737, encodeId=50ff2118e377e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：做个记录，一篇关于罕见转移的临床回顾性研究…… 20230306 submitted 0308 Administrative checks complete……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=997xiu, createdTime=Fri Mar 10 23:08:33 CST 2023, time=2023-03-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1230573, encodeId=670a12305e38a, content=偏重的研究方向：乳腺癌 经验分享：记录一下 6月29日开始邀请审稿人 7月4日仍然还在邀请中........ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=摩西摩西, createdTime=Mon Jul 04 22:29:43 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959975, encodeId=86809599e5dd, content=有没有人遇到过这种情况，一审两个审稿人意见很中肯，修回三天了，状态又成了Selecting Referees，这是什么意思，是在找之前的审稿人还是又重新送审了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1aae2944946, createdName=1033927265, createdTime=Sat Apr 24 10:00:03 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904502, encodeId=6a75904502f4, content=投稿一个月了，现在还是Securing Referees，请问是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKJn00QRPUIQRIfRn1gJOYBXibwFW4ibQuO09ObUInlL9wHCMQW2ADGW7Oibhr7Hqw6TN04s4wQ2z4Qg/132, createdBy=2b8d2258604, createdName=aciding, createdTime=Thu Dec 03 08:41:57 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074335, encodeId=3bbb10e433543, content=5月投稿，这个月初于被接收了，这个期刊审稿速度我觉得还可以啊！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=ASD8888, createdTime=Fri Nov 26 21:50:40 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222662, encodeId=e6c412226621d, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：第一篇SCI 一个月左右返回意见：大修，返修后20天接收还是挺快的不知道什么时候出PROOF, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a0e5183979, createdName=14701b4bm56暂无昵称, createdTime=Thu May 26 21:12:12 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2107072, encodeId=9185210e072ab, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：消化道肿瘤;水凝胶 经验分享：我会经常在梅斯上看大家的经验，想着我要是有经验了也来给大家反馈一下，互相帮助共渡毕业大关： 2022-6-21号投稿 Initial Checks， 6-23号更新投稿 Initial Checks， 6-24号Initial checks have been completed and Editor assignment is being determined， 6-27号Editor assessment The Editor is assessing your submission for peer review， 6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received， 7-4号邮件告知UnderReview，Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews， 8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received， 8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission， 8-19号通知大修， 9-11号R1修回， 10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission， 11-06号催稿信， 12-01号通知二次返修， 12-13号R2修回， 12-22号Accept Admin completing pre-production checks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211124/1e5cd5d4efd7465caf5bd5b725ef80a1/3ece342b14e94d08bab19d7ff6d8dadd.jpg, createdBy=a3015646862, createdName=不懂科研的科研狗子, createdTime=Thu Dec 22 16:38:20 CST 2022, time=2022-12-22, status=1, ipAttribution=北京)]

2021-11-26 ASD8888

5月投稿，这个月初于被接收了，这个期刊审稿速度我觉得还可以啊！

84 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=953030, encodeId=72a3953030a8, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：腮腺癌 经验分享：2021年1月4日投稿，2021年03月17日返回评审建议，两个评审均为小修，3.19反修，3月29日接收，从投稿到接收不到3个月。之前投过一次被拒稿，一共投两次，拒稿率50%。用了SEER数据库建预后模型与TNM分期比较。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/c69458c5aae644fca7458ac4ee7d3dc5/97598ec05e2943409cd351605fd99203.jpg, createdBy=75b92509278, createdName=Lei-Lei, createdTime=Thu Apr 01 10:57:29 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999431, encodeId=c35699943123, content=小修修回去都10天了，还没有消息，各位大神知道这个杂志小修修回一般几天给消息啊等的好焦急啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f634299025, createdName=wangle1256bai, createdTime=Wed Jul 14 16:08:29 CST 2021, time=2021-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077882, encodeId=75f210e78824d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤学;Medicine;肿瘤 经验分享：审稿了这个杂志几篇文章，最后拒了两篇，接收了两篇，总体来说杂志对数据量和创新性要求不高，有一些seer数据库的文章和纯临床文章也会接收，审稿周期可能看寻找审稿人过程顺不顺利，长短不一, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLsIgn717B1AlcC2NErrfSbC5l68ia3bYc7zzhOAFibyeFcu4x6JQcCcqJmy08br2e0M72TM5To33pw/132, createdBy=a7af2090460, createdName=dragon0211, createdTime=Tue Dec 07 22:13:46 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118737, encodeId=50ff2118e377e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：做个记录，一篇关于罕见转移的临床回顾性研究…… 20230306 submitted 0308 Administrative checks complete……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=997xiu, createdTime=Fri Mar 10 23:08:33 CST 2023, time=2023-03-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1230573, encodeId=670a12305e38a, content=偏重的研究方向：乳腺癌 经验分享：记录一下 6月29日开始邀请审稿人 7月4日仍然还在邀请中........ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=摩西摩西, createdTime=Mon Jul 04 22:29:43 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959975, encodeId=86809599e5dd, content=有没有人遇到过这种情况，一审两个审稿人意见很中肯，修回三天了，状态又成了Selecting Referees，这是什么意思，是在找之前的审稿人还是又重新送审了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1aae2944946, createdName=1033927265, createdTime=Sat Apr 24 10:00:03 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904502, encodeId=6a75904502f4, content=投稿一个月了，现在还是Securing Referees，请问是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKJn00QRPUIQRIfRn1gJOYBXibwFW4ibQuO09ObUInlL9wHCMQW2ADGW7Oibhr7Hqw6TN04s4wQ2z4Qg/132, createdBy=2b8d2258604, createdName=aciding, createdTime=Thu Dec 03 08:41:57 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074335, encodeId=3bbb10e433543, content=5月投稿，这个月初于被接收了，这个期刊审稿速度我觉得还可以啊！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=ASD8888, createdTime=Fri Nov 26 21:50:40 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222662, encodeId=e6c412226621d, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：第一篇SCI 一个月左右返回意见：大修，返修后20天接收还是挺快的不知道什么时候出PROOF, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a0e5183979, createdName=14701b4bm56暂无昵称, createdTime=Thu May 26 21:12:12 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2107072, encodeId=9185210e072ab, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：消化道肿瘤;水凝胶 经验分享：我会经常在梅斯上看大家的经验，想着我要是有经验了也来给大家反馈一下，互相帮助共渡毕业大关： 2022-6-21号投稿 Initial Checks， 6-23号更新投稿 Initial Checks， 6-24号Initial checks have been completed and Editor assignment is being determined， 6-27号Editor assessment The Editor is assessing your submission for peer review， 6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received， 7-4号邮件告知UnderReview，Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews， 8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received， 8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission， 8-19号通知大修， 9-11号R1修回， 10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission， 11-06号催稿信， 12-01号通知二次返修， 12-13号R2修回， 12-22号Accept Admin completing pre-production checks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211124/1e5cd5d4efd7465caf5bd5b725ef80a1/3ece342b14e94d08bab19d7ff6d8dadd.jpg, createdBy=a3015646862, createdName=不懂科研的科研狗子, createdTime=Thu Dec 22 16:38:20 CST 2022, time=2022-12-22, status=1, ipAttribution=北京)]

2022-05-26 14701b4bm56暂无昵称

审稿速度:1.0
偏重的研究方向：肿瘤
经验分享：第一篇SCI 一个月左右返回意见：大修，返修后20天接收还是挺快的不知道什么时候出PROOF

48 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=953030, encodeId=72a3953030a8, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：腮腺癌 经验分享：2021年1月4日投稿，2021年03月17日返回评审建议，两个评审均为小修，3.19反修，3月29日接收，从投稿到接收不到3个月。之前投过一次被拒稿，一共投两次，拒稿率50%。用了SEER数据库建预后模型与TNM分期比较。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/c69458c5aae644fca7458ac4ee7d3dc5/97598ec05e2943409cd351605fd99203.jpg, createdBy=75b92509278, createdName=Lei-Lei, createdTime=Thu Apr 01 10:57:29 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999431, encodeId=c35699943123, content=小修修回去都10天了，还没有消息，各位大神知道这个杂志小修修回一般几天给消息啊等的好焦急啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f634299025, createdName=wangle1256bai, createdTime=Wed Jul 14 16:08:29 CST 2021, time=2021-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077882, encodeId=75f210e78824d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤学;Medicine;肿瘤 经验分享：审稿了这个杂志几篇文章，最后拒了两篇，接收了两篇，总体来说杂志对数据量和创新性要求不高，有一些seer数据库的文章和纯临床文章也会接收，审稿周期可能看寻找审稿人过程顺不顺利，长短不一, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLsIgn717B1AlcC2NErrfSbC5l68ia3bYc7zzhOAFibyeFcu4x6JQcCcqJmy08br2e0M72TM5To33pw/132, createdBy=a7af2090460, createdName=dragon0211, createdTime=Tue Dec 07 22:13:46 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118737, encodeId=50ff2118e377e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：做个记录，一篇关于罕见转移的临床回顾性研究…… 20230306 submitted 0308 Administrative checks complete……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=997xiu, createdTime=Fri Mar 10 23:08:33 CST 2023, time=2023-03-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1230573, encodeId=670a12305e38a, content=偏重的研究方向：乳腺癌 经验分享：记录一下 6月29日开始邀请审稿人 7月4日仍然还在邀请中........ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=摩西摩西, createdTime=Mon Jul 04 22:29:43 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959975, encodeId=86809599e5dd, content=有没有人遇到过这种情况，一审两个审稿人意见很中肯，修回三天了，状态又成了Selecting Referees，这是什么意思，是在找之前的审稿人还是又重新送审了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1aae2944946, createdName=1033927265, createdTime=Sat Apr 24 10:00:03 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904502, encodeId=6a75904502f4, content=投稿一个月了，现在还是Securing Referees，请问是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKJn00QRPUIQRIfRn1gJOYBXibwFW4ibQuO09ObUInlL9wHCMQW2ADGW7Oibhr7Hqw6TN04s4wQ2z4Qg/132, createdBy=2b8d2258604, createdName=aciding, createdTime=Thu Dec 03 08:41:57 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074335, encodeId=3bbb10e433543, content=5月投稿，这个月初于被接收了，这个期刊审稿速度我觉得还可以啊！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=ASD8888, createdTime=Fri Nov 26 21:50:40 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222662, encodeId=e6c412226621d, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：第一篇SCI 一个月左右返回意见：大修，返修后20天接收还是挺快的不知道什么时候出PROOF, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a0e5183979, createdName=14701b4bm56暂无昵称, createdTime=Thu May 26 21:12:12 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2107072, encodeId=9185210e072ab, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：消化道肿瘤;水凝胶 经验分享：我会经常在梅斯上看大家的经验，想着我要是有经验了也来给大家反馈一下，互相帮助共渡毕业大关： 2022-6-21号投稿 Initial Checks， 6-23号更新投稿 Initial Checks， 6-24号Initial checks have been completed and Editor assignment is being determined， 6-27号Editor assessment The Editor is assessing your submission for peer review， 6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received， 7-4号邮件告知UnderReview，Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews， 8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received， 8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission， 8-19号通知大修， 9-11号R1修回， 10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission， 11-06号催稿信， 12-01号通知二次返修， 12-13号R2修回， 12-22号Accept Admin completing pre-production checks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211124/1e5cd5d4efd7465caf5bd5b725ef80a1/3ece342b14e94d08bab19d7ff6d8dadd.jpg, createdBy=a3015646862, createdName=不懂科研的科研狗子, createdTime=Thu Dec 22 16:38:20 CST 2022, time=2022-12-22, status=1, ipAttribution=北京)]

2022-12-22 不懂科研的科研狗子来自北京

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：消化道肿瘤;水凝胶
经验分享：我会经常在梅斯上看大家的经验，想着我要是有经验了也来给大家反馈一下，互相帮助共渡毕业大关：
2022-6-21号投稿 Initial Checks，
6-23号更新投稿 Initial Checks，
6-24号Initial checks have been completed and Editor assignment is being determined，
6-27号Editor assessment The Editor is assessing your submission for peer review，
6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received，
7-4号邮件告知UnderReview，Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews，
8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received，
8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission，
8-19号通知大修，
9-11号R1修回，
10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission，
11-06号催稿信，
12-01号通知二次返修，
12-13号R2修回，
12-22号Accept Admin completing pre-production checks.

160 5

展开5条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务